School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China.
Department of Pharmacy, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, China.
Cancer Chemother Pharmacol. 2023 Sep;92(3):165-179. doi: 10.1007/s00280-023-04541-8. Epub 2023 Jul 6.
As a new means of oncology treatment, immune checkpoint inhibitors (ICIs) can improve survival rates in patients with resistant or refractory tumors. However, there are obvious inter-individual differences in the unsatisfactory response rate, drug resistance rate and the occurrence of immune-related adverse events (irAE). These questions have sparked interest in researchers looking for a way to screen sensitive populations and predict efficacy and safety. Therapeutic drug monitoring (TDM) is a way to ensure the safety and effectiveness of medication by measuring the concentration of drugs in body fluids and adjusting the medication regimen. It has the potential to be an adjunctive means of predicting the safety and efficacy of ICIs treatment. In this review, the author outlined the pharmacokinetic (PK) characteristics of ICIs in patients. The feasibility and limitations of TDM of ICIs were discussed by summarizing the relationships between the pharmacokinetic parameters and the efficacy, toxicity and biomarkers.
作为一种新的肿瘤治疗手段，免疫检查点抑制剂（ICI）可以提高耐药或难治性肿瘤患者的生存率。然而，在不满意的反应率、耐药率和免疫相关不良事件（irAE）的发生方面，个体间存在明显差异。这些问题引起了研究人员的兴趣，他们正在寻找一种筛选敏感人群以及预测疗效和安全性的方法。治疗药物监测（TDM）是通过测量体液中药物浓度并调整药物治疗方案来确保药物安全性和有效性的一种方法。它有可能成为预测 ICI 治疗安全性和疗效的辅助手段。在这篇综述中，作者概述了患者体内 ICI 的药代动力学（PK）特征。通过总结药代动力学参数与疗效、毒性和生物标志物之间的关系，讨论了 TDM 的可行性和局限性。
